
1 No-Brainer AI Stock That Could Soar By 150% In 5 Years
The long-term returns for the broader stock market are about 10% annually, which causes the market to double around once every seven years. So, if you can pinpoint stocks that can soar 150% over the next five years, you'll have a great chance of beating the market with some margin of safety built in.
One AI stock I've identified that can achieve that is Taiwan Semiconductor Manufacturing (NYSE: TSM). Taiwan Semiconductor is the leading chip fabricator worldwide and has nearly every big tech company as a client for its chips. Thanks to Taiwan Semiconductor's positioning, it can accurately project years into the future, which is where the 150% return level comes from.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
If you want to add another stock to your portfolio or increase your current TSMC holding, now could be an excellent time before the market wakes up to Taiwan Semiconductor's substantial opportunity.
Taiwan Semiconductor is positioned to succeed over the next five years
Taiwan Semiconductor, or TSMC, is a chip fabricator, and these orders are often placed years in advance due to high demand. For example, Taiwan Semiconductor's existing Arizona facility already sold out production through 2027, which means it likely has orders in its system for that facility through at least 2028. While there are some tariff concerns, semiconductors are exempt from reciprocal tariff levies as of this moment (although that could easily change). Furthermore, TSMC's CEO C.C. Wei stated in its first-quarter conference call that "we have not seen any change in our customers' behavior so far" when commenting on tariffs.
Taiwan Semiconductor is more than generous with information to investors, offering monthly revenue updates throughout the year. In April, its revenue (in New Taiwan Dollars) was up 48% year over year and 40% in May. These numbers can fluctuate from year to year depending on how many working days there are from year to year (there were 23 working days in May during 2024 while only 22 in 2025), but it's still useful to check in on TSMC to get an idea of any large demand shifts.
Clearly, Taiwan Semiconductor is doing great, but the 150% increase projection deals with the next five years, not the next five months. Management's long-term guidance given at the beginning of 2025 was for the company to grow AI-related revenue at a compounded annual growth rate (CAGR) of 45% for the next five years. That means AI-related revenue will rise 541% over the next five years. Overall revenue is expected to rise at nearly a 20% CAGR. If it achieves that level, then revenue will increase at a 149% pace.
With fully mature companies like Taiwan Semiconductor, stock performance can be tied to revenue growth if margins aren't shrinking. Otherwise, returns are highly correlated to profit growth. As long as TSMC maintains its margins, profit and revenue growth likely will be equal.
However, there is one caveat to this argument.
Taiwan Semiconductor's stock trades at an attractive level
Correlating stock returns with revenue growth is only true if the valuation is reasonable. A contracting multiple can wipe out a ton of revenue growth, but fortunately for investors, TSMC is valued at a reasonable level.
At 22.9 times forward earnings, Taiwan Semiconductor is trading at nearly the same level as the broader market, as measured by the S&P 500 index, which trades at 22.5 times forward earnings.
TSM PE Ratio (Forward) data by YCharts
Common sense would lead investors to believe that because TSMC is expected to grow faster than the market, it should be valued at a premium to the market, but that's not the case.
This mismatch will allow investors the chance to make a huge profit from buying and holding TSMC's stock for the next few years. Taiwan Semiconductor is one of the best stocks to buy on the market, and with its neutral position in the AI arms race, it's about as close as it gets to a surefire investment in the AI realm.
Should you invest $1,000 in Taiwan Semiconductor Manufacturing right now?
Before you buy stock in Taiwan Semiconductor Manufacturing, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Taiwan Semiconductor Manufacturing wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,702!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $870,207!*
Now, it's worth noting Stock Advisor 's total average return is988% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of June 9, 2025
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
2 hours ago
- Globe and Mail
Palantir vs. CrowdStrike: Which Stock Is Worth Holding Forever?
Two of AI's hottest stocks -- Palantir (NASDAQ: PLTR) and CrowdStrike (NASDAQ: CRWD) -- are soaring on the back of game-changing innovations. Each dominates its niche, but one boasts a stronger moat and better profitability profile. Here's why one of these AI leaders could deliver explosive upside for investors in 2025 and beyond. *Stock prices used were the market prices of June 6, 2025. The video was published on June 16, 2025. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 988%* — a market-crushing outperformance compared to 172% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of June 9, 2025 Rick Orford has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CrowdStrike and Palantir Technologies. The Motley Fool has a disclosure policy.


Globe and Mail
2 hours ago
- Globe and Mail
New Toll Brothers Stonegate Court Model Home Opens in Gilbert, Arizona
GILBERT, Ariz., June 16, 2025 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation's leading builder of luxury homes, announced the grand opening of its model home at Stonegate Court, an exclusive new gated community featuring just 22 expansive single-story homes on 15,000+ square foot home sites in Gilbert, Arizona. The stunning Markham model home showcases beautiful farmhouse architecture with fresh modern organic interior design and an incredible resort-style backyard. The Toll Brothers model home grand opening event at Stonegate Court will be held on Saturday, June 21 from 11 a.m. to 4 p.m. at 4229 S. Quinn Ave. in Gilbert. 'The newly opened Markham model home exemplifies the exceptional luxury designs that Toll Brothers offers at Stonegate Court, providing home shoppers with a first-hand look at the sophisticated features and finishes that define Toll Brothers homes,' said Bob Flaherty, Group President of Toll Brothers in Arizona. Quietly tucked between a handful of well-established neighborhoods, Stonegate Court's enclave-like setting offers homebuyers an ideal blend of sophisticated living and modern convenience. The community features three, single-level floor plans ranging from 3,466 to 4,126+ square-feet with 3 to 6 bedrooms, 3.5 to 5.5 baths, and 3- to 4-car garages, with a wide array of personalization options including private multi-generational living suites, expansive multi-slide doors, courtyards, wine rooms, exterior fireplaces, and more. Homes are priced starting at $1.38 million. The intimate setting of the community provides a serene escape for residents, while being ideally located within the desirable Higley Unified School District and near major commuter routes and premier shopping, dining, and outdoor recreation. Toll Brothers customers will experience one-stop shopping at the Toll Brothers Design Studio. The state-of-the-art Design Studio allows customers to choose from a wide array of selections to personalize their dream home with the assistance of Toll Brothers professional Design Consultants. For more information on Stonegate Court or other Toll Brothers communities in Arizona, call (844) 836-5263 or visit Stonegate About Toll Brothers Toll Brothers, Inc., a Fortune 500 Company, is the nation's leading builder of luxury homes. The Company was founded 58 years ago in 1967 and became a public company in 1986. Its common stock is listed on the New York Stock Exchange under the symbol 'TOL.' The Company serves first-time, move-up, empty-nester, active-adult, and second-home buyers, as well as urban and suburban renters. Toll Brothers builds in over 60 markets in 24 states: Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Indiana, Maryland, Massachusetts, Michigan, Nevada, New Jersey, New York, North Carolina, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Virginia, and Washington, as well as in the District of Columbia. The Company operates its own architectural, engineering, mortgage, title, land development, smart home technology, and landscape subsidiaries. The Company also develops master-planned and golf course communities as well as operates its own lumber distribution, house component assembly, and manufacturing operations. Toll Brothers has been one of Fortune magazine's World's Most Admired Companies™ for 10+ years in a row, and in 2024 the Company's Chairman and CEO Douglas C. Yearley, Jr. was named one of 25 Top CEOs by Barron's magazine. Toll Brothers has also been named Builder of the Year by Builder magazine and is the first two-time recipient of Builder of the Year from Professional Builder magazine. For more information visit From Fortune, ©2025 Fortune Media IP Limited. All rights reserved. Used under license.

National Post
2 hours ago
- National Post
SAIF Partners Files Definitive Proxy Materials in Connection with Sinovac Biotech 2025 Special Meeting of Shareholders; Nominates Ten Highly Qualified Director Candidates to the Board
Article content Sends Open Letter to Sinovac Shareholders Calling for a New Board to End Years of Chaos at Sinovac Article content SAIF Nominees Will Work to Resolve Costly Legal Battles, Take Action to Resume Stock Trading after Six-Year Halt, and Facilitate Distribution of Cash That Rightfully Belongs to Shareholders Article content Article content Urges Sinovac Shareholders to VOTE the GOLD Proxy Card FOR the Election of SAIF's Director Nominees Article content BEIJING — SAIF Partners IV L.P., ('SAIF Partners'), the largest single investor in Sinovac Biotech Ltd. ('Sinovac' or the 'Company'), beneficially owning approximately 15% of the outstanding common shares, today announced that it has filed a definitive proxy statement for the election of ten director nominees to Sinovac's Board of Directors (the 'Board') in connection with the special meeting of the shareholders of the Company to be held on Tuesday, July 8, 2025 at 8 p.m. Atlantic Standard Time (Wednesday, July 9, 2025 at 8:00 a.m. China Standard Time), and at any adjourned, postponed, continued, or rescheduled meeting thereof (the 'Special Meeting'). Article content Additionally, SAIF Partners issued an open letter to its fellow Sinovac shareholders outlining its belief that new highly qualified directors are required to effectively resolve the significant challenges Sinovac currently faces and deliver value for all shareholders. In the letter, SAIF details how the Board has not effectively guided Sinovac after the significant chaos of the past several years, including, among other issues, strategic missteps, costly and distracting legal battles, a stock that does not trade, and a large amount of cash that the Company is inexplicably retaining rather than distributing it to shareholders as they should. Article content If elected, SAIF Partners' nominees will work with management to develop a plan to address these issues and bring disciplined corporate governance, proper capital allocation, strategic foresight and operational excellence to Sinovac. SAIF Partners has outlined the most critical priorities for Sinovac that their nominees would seek to address if elected, including declaring additional dividends, resuming trading of common shares and resolving shareholder disputes. Article content The full text of the letter is below. Article content June 16, 2025 Article content Dear Fellow Sinovac Shareholder: Article content As the largest single investor and a long-term shareholder in Sinovac Biotech Ltd. ('Sinovac' or the 'Company'), beneficially owning approximately 15% of the outstanding common shares, SAIF Partners ('SAIF') believes deeply in the Company's products and tremendous potential to create long-lasting value for all shareholders. However, Sinovac's Board of Directors (the 'Board') has not effectively guided Sinovac after the significant chaos of the past several years, including, among other issues, strategic missteps, costly and distracting legal battles, a stock that does not trade, and a large amount of cash that the Company is inexplicably retaining rather than distributing it to shareholders as they should. Article content The Board has done nothing to address these issues and only began to acknowledge them after we forced Sinovac to hold a special meeting to replace directors. Simply put, the status quo is not working. Article content Sinovac desperately needs new and experienced directors dedicated to putting Sinovac back on the right track through disciplined corporate governance, proper capital allocation, strategic foresight and operational excellence – and acting in the best interests of ALL Sinovac shareholders. As such, SAIF is nominating highly qualified candidates for election to the Board at the special meeting of shareholders to be held July 8, 2025. Article content We have taken this important action to address key issues at Sinovac that, if elected, will be top priorities for our nominees, including: Article content 1. Declaration of Additional Dividend. We believe there are billions of US dollars of available cash in Sinovac's accounts and that Sinovac can and should pay more dividends to shareholders in addition to the $55.00 per share special dividend declared by the Board on April 1, 2025, which would not have been announced without our engagement. Further, dividends have been paid from Sinovac subsidiaries, but not to shareholders. Our nominees will determine, in close collaboration with management, on the appropriate allocation of retained earnings and facilitate the distribution of long-overdue returns to all shareholders. Article content 2. Resumption of Trading of Common Shares of the Company. Sinovac shares have not traded for more than six years, denying shareholders the liquidity they deserve. Article content Our nominees will take immediate steps to address compliance issues and work expeditiously towards the resumption of trading of the Company's shares. Article content 3. Resolution of Shareholder Disputes and Unlocking the Company's Full Potential. Sinovac has been entrapped in endless disputes and prolonged lawsuits since 2018. We are concerned that the series of legal disputes started recently will cause more crisis and destruction to the interests of the Company and its shareholders. Article content Our nominees will engage with these shareholders to amicably resolve ongoing disputes, eliminate divisions, and foster alignment among shareholders in order to focus on Sinovac's core mission, and drive growth and value. Article content 4. Strategic Realignment for Shareholder Value Creation. Sinovac's Board does not currently have a strategic plan in place that reflects the realities of the current market environment and positions the Company to capitalize on emerging opportunities in the biopharmaceutical sector. Article content Our nominees will work closely with Sinovac management to develop a business strategy with clear operational objectives to drive long-term value for all shareholders. Article content A NEW BOARD IS DESPERATELY NEEDED TO RESTORE CREDIBILITY AND ENSURE Article content Sinovac shareholders deserve a Board that is unbiased in its decision making and dedicated to acting on behalf of all shareholders rather than for a select few. Presently, all but one member of the Board are representatives of 1Globe and OrbiMed, whose influence far exceeds their respective 9.5% and 3.8% ownership stakes in Sinovac. Article content We believe our nominees – who represent a broad base of major Sinovac shareholders including Weidong Yin (the CEO and founder of the Company), SAIF Partners, Vivo Capital, CDH Investment, Advantech Capital, and 1Globe – will comprise a well-balanced and diversified Board with extensive industry knowledge, experience and insights necessary to end costly and distracting internal strife, and execute a clear strategic plan that maximizes sustainable, long-term value for ALL shareholders. Certain of our nominees have key management experience at Sinovac and will work closely with the Company management team to drive long-term value for all shareholders. Article content We urge you to join us and vote the GOLD proxy card in support of our highly qualified nominees who will make the changes necessary to help Sinovac realize its tremendous potential and build the value of Sinovac for all shareholders. Article content SAIF Partners Article content About SAIF Partners Article content SAIF Partners is a leading Asian private equity firm with cumulative assets under management of over $4 billion. SAIF Partners is an active lead investor working closely with its portfolio companies to develop their business both organically and through acquisitions, seeking synergistic cooperation among them, as well as enhancing shareholder value via promotion of good corporate governance and best management practices. Article content Additional Information and Where to Find It Article content This communication may be deemed to be solicitation material in respect of SAIF Partners' nomination of ten director nominees to Sinovac's Board. In connection with such solicitation, SAIF Partners mailed the definitive proxy statement and proxy card to shareholders of Sinovac with respect to the Special Meeting to be held in connection with the election of directors to Sinovac's Board. The definitive proxy statement mailed by SAIF Partners is also filed as Exhibit 1 to its Schedule 13D/A filed on or about June 16, 2025. SHAREHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE COMPANY WILL MAIL AND FILE WITH THE SEC IN CONNECTION WITH THE SINOVAC SPECIAL MEETING, INCLUDING ANY DOCUMENT INCORPORATED BY REFERENCE THEREIN, CAREFULLY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE DIRECTOR NOMINEES AND THE SPECIAL MEETING AND RELATED MATTERS. Sinovac's shareholders may obtain, free of charge, the definitive version of the proxy statement, any amendments or supplements thereto, and any other relevant documents mailed by SAIF Partners in connection with the Special Meeting at Article content Article content Article content Contacts Article content Media Contacts Article content Article content Jonathan Gasthalter/Mark Semer/Grace Cartwright Article content Article content Gasthalter & Co. Article content Article content +1 (212) 257 4170 Article content Article content SAIF@ Article content Investor Contacts Article content Article content Paul Schulman/Bill Dooley/Jon Eyl Article content Article content Sodali & Co. Article content Article content Article content